Sunovion Pharms Inc patents expiration
1. Aptiom patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9206135 | SUNOVION PHARMS INC | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11364247 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 7 months from now) | |
| US10675287 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 7 months from now) | |
| US10695354 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 7 months from now) | |
| US10702536 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 7 months from now) | |
| US9643929 | SUNOVION PHARMS INC | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(2 years from now) | |
| US9763954 | SUNOVION PHARMS INC | Therapeutical uses of eslicarbazepine |
Sep, 2028
(4 years from now) | |
| US10912781 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(5 years from now) | |
| US9566244 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(5 years from now) | |
| US8372431 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Apr, 2030
(6 years from now) | |
| US9750747 | SUNOVION PHARMS INC | Treatments involving eslicarbazepine acetate or eslicarbazepine |
Aug, 2032
(8 years from now) | |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
Market Authorisation Date: 08 November, 2013
Treatment: Treatment of partial-onset seizures; Treatment of partial-onset seizures in a patient with refractory partial-onset seizures; Treatment of partial-onset seizures in patients with epilepsy who have bee...
Dosage: TABLET;ORAL
APTIOM family patents
2. Kynmobi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9931305 | SUNOVION PHARMS INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Feb, 2022
(1 year, 7 months ago) | |
| US10888499 | SUNOVION PHARMS INC | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
Feb, 2022
(1 year, 7 months ago) | |
| US9855221 | SUNOVION PHARMS INC | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(1 year, 7 months ago) | |
| US11077068 | SUNOVION PHARMS INC | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(1 year, 7 months ago) | |
| US8663687 | SUNOVION PHARMS INC | Film compositions for delivery of actives |
Feb, 2023
(7 months ago) | |
| US8765167 | SUNOVION PHARMS INC | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2024
(4 months from now) | |
| US8603514 | SUNOVION PHARMS INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(6 months from now) | |
| US10821074 | SUNOVION PHARMS INC | Sublingual and buccal film compositions |
Aug, 2029
(5 years from now) | |
| US10420763 | SUNOVION PHARMS INC | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9283219 | SUNOVION PHARMS INC | Sublingual films |
Jun, 2030
(6 years from now) | |
| US9326981 | SUNOVION PHARMS INC | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9669019 | SUNOVION PHARMS INC | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9669021 | SUNOVION PHARMS INC | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US9044475 | SUNOVION PHARMS INC | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
| US8414922 | SUNOVION PHARMS INC | Sublingual films |
Dec, 2031
(8 years from now) | |
| US11419769 | SUNOVION PHARMS INC | Sublingual films |
Dec, 2031
(8 years from now) | |
| US8846074 | SUNOVION PHARMS INC | Sublingual films |
Dec, 2031
(8 years from now) | |
| US10959943 | SUNOVION PHARMS INC | Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa |
Apr, 2036
(12 years from now) | |
| US10449146 | SUNOVION PHARMS INC | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
Apr, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | May 21, 2023 |
Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 May, 2020
Treatment: Treatment of 'off' episodes in patients with parkinson's disease
Dosage: FILM;SUBLINGUAL
KYNMOBI family patents
3. Latuda patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE45573 | SUNOVION PHARMS INC | Process for producing imide compound |
Jun, 2025
(1 year, 8 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9174975 | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Feb, 2024
(4 months from now) | |
| US9815827 | SUNOVION PHARMS INC | Agent for treatment of schizophrenia |
Feb, 2024
(4 months from now) | |
|
US9174975 (Pediatric) | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Aug, 2024
(10 months from now) | |
|
USRE45573 (Pediatric) | SUNOVION PHARMS INC | Process for producing imide compound |
Dec, 2025
(2 years from now) | |
| US9907794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
| US9555027 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
| US8729085 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
| US8883794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
|
US9907794 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(3 years from now) | |
|
US8883794 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(3 years from now) | |
|
US8729085 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(3 years from now) | |
| US9827242 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(7 years from now) | |
| US9259423 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(7 years from now) | |
|
US9259423 (Pediatric) | SUNOVION PHARMS INC | Method of treatment for mental disorders |
Nov, 2031
(8 years from now) | |
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 October, 2010
Treatment: Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia; Treatment of major depressive episodes associated with bipolar i disorder; Treatment of ...
Dosage: TABLET;ORAL
LATUDA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic